Abstract
Objective
To compare the effectiveness of acupuncture alone or with additional integrative oncology modalities for taxane-induced peripheral neuropathy-related symptoms in patients with gynecological and breast cancer.
Methods
The study was a prospective evaluation of patients undergoing twice-weekly treatments with either acupuncture alone (single-modality, group A) or with additional manual-movement and mind-body therapies (multimodality, group B), for 6 weeks. Symptom severity was assessed at baseline, 6 weeks, and 9 weeks using the Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) tool; and von Frey perception thresholds. Additional symptoms were also assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the Measure Yourself Concerns and Wellbeing (MYCaW) study tool.
Results
For the 120 participants (60 in each study arm), baseline to 6-week scores were similar in both groups for improved FACT-Tax physical wellbeing and scores for hand numbness/tingling; EORTC physical functioning and global health status; and MYCaW scores. FACT-Tax taxane subscales and scores for foot numbness/tingling improved only in group A (p=0.038), while emotional wellbeing FACT-Tax (p=0.02) and EORTC pain (p=0.005) improved only in group B. Group B showed greater improvement for FACT-Tax neuropathy-related concerns than group A at 24 hours (p=0.043) and 7 days (p=0.009) after the first treatment.
Conclusion
Acupuncture alone or with additional integrative oncology modalities may help reduce neuropathy-related symptoms. The single-modality group demonstrated greater improvement for foot numbness/tingling, and the multimodality group demonstrated improvement for pain and improved emotional wellbeing and neuropathy-related concerns in the first week of treatment.
Trial registration number: NCT03290976.
Autoren
Eran Ben-Arye, Dorit Gamus, Noah Samuels, Elad Schiff, David Hausner, Orit Gressel, Samuel Attias, Ofer Lavie, Adi David, Katerina Shulman, Abed Agbarya
Journal
Int J Gynecol Cancer. 2023 May 1;33(5):792-801. doi: 10.1136/ijgc-2022-004004.
Link: https://ijgc.bmj.com/content/33/5/792.long
Kommentar
Le 3, MP 4, MP 6, Ma 36, Gb 34, Ni 3, Le 8, Bafeng, Di 4, Di 11, Di 10, PC 6, SJ 3, Sj 4, SJ 5